Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Block Up Over 15%, on Track for Highest Close Since February 2025 -- Data Talk

Block Up Over 15%, on Track for Highest Close Since February 2025 -- Data Talk

Dow JonesDow Jones2026/11/04 15:39

Block Inc. (XYZ) is currently at $87.8, up $11.8 or 15.53%

--Would be highest close since Feb. 3, 2025, when it closed at $90.20

--On pace for largest percent increase since Feb. 27, 2026, when it rose 16.82%

--Currently up five of the past seven days

--Up 34.89% year-to-date; on pace for best year since 2020, when it rose 247.89%

--Down 68.84% from its all-time closing high of $281.81 on Aug. 5, 2021

--Up 19.21% from 52 weeks ago (Nov. 5, 2025), when it closed at $73.65

--Would be a new 52-week closing high

--Up 78.86% from its 52-week closing low of $49.09 on Feb. 12, 2026

--Traded as high as $88.24; highest intraday level since Feb. 7, 2025, when it hit $88.73

--Up 16.11% at today's intraday high; largest intraday percent increase since Feb. 27, 2026, when it rose as much as 21.25%

--Best performer in the S&P 500 today

All data as of 10:37:34 AM EST

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

November 04, 2026 10:39 ET (15:39 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny

CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.

智通财经•2026/11/09 06:37
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny